
Please try another search
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Name | Age | Since | Title |
---|---|---|---|
Patrick James Heron | 55 | 2020 | Independent Director |
Steven L. Hoerter | 54 | 2025 | Independent Director |
Peter Kent Hawryluk | 56 | 2019 | CEO, President & Director |
Steven W. Ryder | 73 | 2024 | Independent Director |
Michael J. Econs | - | 2024 | Member of Scientific Advisory Board |
Edward T. Mathers | 65 | 2020 | Independent Director |
James Milton Cornelius | 82 | 2020 | Independent Director |
Mishaela Rubin | - | 2024 | Member of Scientific Advisory Board |
Tiba Aynechi | 49 | 2022 | Independent Director |
John P. Bilezikian | - | - | Member of Scientific Advisory Board |
Ora Hirsch Pescovitz | 68 | 2022 | Independent Director |
Delores Shoback | - | 2024 | Member of Scientific Advisory Board |
Willard H. Dere | 71 | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review